公开(公告)号：US11643682B2

公开(公告)日：2023-05-09

申请号：US17900619

申请日：2022-08-31

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Charles Gawad ,  John Easton ,  Veronica Gonzalez-Pena

IPC: C12Q1/686 ,  C12N15/10 ,  C12Q1/6869 ,  C12Q1/6883

CPC classification number: C12Q1/686 ,  C12N15/1093 ,  C12Q1/6869 ,  C12Q1/6883 ,  C12Q2600/156

Abstract: Provided herein are compositions and methods for accurate and scalable Primary Template-Directed Amplification (PTA) nucleic acid amplification and sequencing methods, and their applications for research, diagnostics, and treatment.

公开(公告)号：US20230030680A1

公开(公告)日：2023-02-02

申请号：US17791181

申请日：2021-01-06

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stephen GOTTSCHALK ,  Laurens SAND ,  Shannon LANGE

IPC: C07K14/715 ,  A61K35/17

Abstract: The present invention provides chimeric cytokine receptors, particularly chimeric cytokine receptors that canbe activated in tumor microenvironment, and their uses in tumor immunotherapy (e.g., adoptive cell therapy). The present invention further provides methods of genetically modifying therapeutic cells resulting in an enhanced immune response against a target antigen. The application further provides therapeutic cells that express said chimeric cytokine receptors and methods for treating patients using the modified therapeutic cells.

公开(公告)号：US11547709B2

公开(公告)日：2023-01-10

申请号：US16957996

申请日：2018-12-26

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. ,  COA THERAPEUTICS, INC.

Inventor： Suzanne Jackowski ,  Charles O. Rock ,  Richard E. Lee ,  Lalit Kumar Sharma ,  Mi Kyung Yun ,  Chitra Subramanian ,  Rajendra P. Tangallapally ,  Anne V. Edwards ,  Robert Zamboni ,  T. Jagadeeswar Reddy ,  Jiuyu Liu

IPC: A61K31/501 ,  A61P3/00 ,  A61K31/197 ,  A61K31/205

Abstract: The present disclosure relates to methods of treating a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20220226380A1

公开(公告)日：2022-07-21

申请号：US17605639

申请日：2020-04-23

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Hongbo CHI ,  Jun WEI ,  Terrence GEIGER ,  Wenting ZHENG

IPC: A61K35/17 ,  C12N15/90 ,  C12N15/11 ,  C12N9/22 ,  C12N9/10 ,  C12N9/16 ,  A61P35/00 ,  C07K14/47 ,  A61K38/46 ,  A61K31/7088 ,  C12N15/86 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725

Abstract: The present application provides methods of enhancing T cell function (e.g., expansion, persistence and/or effector functions), particularly by genetic modification of the Regnase-1, Batf, and additional genes (alone or in combination). The application also provides modified T cells manufactured using the methods provided by this invention and related pharmaceutical compositions. The application further provides methods of using the modified T cells for treating a disease (e.g., a cancer or an infectious disease).

公开(公告)号：US20220226379A1

公开(公告)日：2022-07-21

申请号：US17602524

申请日：2020-04-08

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Stephen GOTTSCHALK ,  Giedre KRENCIUTE ,  Christopher PETERSEN ,  Benjamin YOUNGBLOOD

IPC: A61K35/17 ,  A61P35/02 ,  A61K35/545 ,  C12N9/10

Abstract: The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and STAT5 signaling pathway is activated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.

公开(公告)号：US11371095B2

公开(公告)日：2022-06-28

申请号：US17166549

申请日：2021-02-03

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Shengdar Q. Tsai ,  Cicera R. Lazzarotto

IPC: C12Q1/6874 ,  C12N15/10 ,  C40B40/06 ,  C40B50/06

Abstract: The invention relates to a high-throughput method for characterizing the genome-wide activity of editing nucleases in vitro.

公开(公告)号：US20220125805A1

公开(公告)日：2022-04-28

申请号：US17428812

申请日：2020-02-06

Applicant: UNIVERSIDAD CENTRAL DEL CARIBE ,  ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Michelle M. MARTINEZ-MONTEMAYOR ,  Fatima RIVAS

IPC: A61K31/575 ,  A61K36/074 ,  A61K47/20 ,  A61P35/00 ,  G01N33/58

Abstract: The bioactive compounds of Ganoderma lucidum extract (GLE) responsible for anticancer activity were elucidated using NMR, X-ray crystallography and analogue derivatization, as well as anti-cancer activity studies. Structures of the seven most abundant GLE compounds are disclosed. Their selective efficacy against triple negative (TNBC) and inflammatory breast cancers (IBC) and other human cancer cell types (solid and blood malignancies) was shown, confirming potential their as anticancer agents.

公开(公告)号：US11268158B2

公开(公告)日：2022-03-08

申请号：US15136298

申请日：2016-04-22

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Brian P. Sorrentino ,  Sheng Zhou

IPC: C12Q1/70

Abstract: The invention is directed to methods of assessing the safety of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing. In particular, the invention provides a method, wherein the oncogenic potential of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing, is determined by determining the percentage of differentiation blocked hematopoietic progenitor cells.

公开(公告)号：US20210388012A1

公开(公告)日：2021-12-16

申请号：US17288493

申请日：2018-11-05

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Richard E. LEE ,  Jiuyu LIU

IPC: C07F9/6561 ,  C07D493/04 ,  A61K45/06

Abstract: In one aspect, the disclosure relates to substituted spectinomycin analogs, including substituted aminomethyl spectinomycin analogs and substituted spectinamide analogs, with increased tolerability and safety, including improved tolerability to parenteral administration. The present disclosure further pertains to methods of making disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating microbial infections using the disclosed compounds, including methods of treating antibiotic resistant infections and tuberculosis. This abstract is intended as a scanning tool for pur-poses of searching in the particular art and is not intended to be limiting of the present disclosure.

公开(公告)号：US11103597B2

公开(公告)日：2021-08-31

申请号：US15573684

申请日：2016-05-13

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： John T. Gray

IPC: C12N15/86 ,  A61K48/00 ,  A61K35/76 ,  C12N7/00 ,  C12N15/861

Abstract: The present invention relates to nucleic acid molecules containing spacers that can be packaged into viral particles and methods of producing them. In a first aspect, the invention features a nucleic acid molecule including a first spacer (SSI); a first inverted terminal repeat (ITR1); a cloning site (CS); a second inverted terminal repeat (ITR2); and a second spacer (SS2), such as a eukaryotic spacer; operably linked to each other in a 5′-to-3′ direction as: SS1-ITR1-CS-ITR2-SS2. In an embodiment, the invention features a vector comprising any of the above-described nucleic acid molecules. In another aspect, the invention features a plurality of viral particles including the nucleic acid molecule. The invention further includes a host cell including any of the above-described vectors.